Skanska has received a contract worth $120m from NYU Langone Medical Centre to construct a new medical centre in New York City, US.
As part of the deal, Skanska will construct a 15,000ft² five-story ambulatory care centre. It will include an emergency department, surgical and imaging suites, a pharmacy and physician office space.
Pre-construction services of the project have commenced and it is expected to be completed in October 2017.
NYU Langone’s breast surgery division deployed MarginProbe for early stage breast cancer.
Developed by Dune Medical Devices, MarginProbe uses non-destructive radio-frequency spectroscopy technology in the operating room to analyse outer margins of removed cancerous tissue to detect traces of cancer cells.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The surgeon excises additional tissue from the surgical site to ensure no additional cancer cells remain, if cancer cells are detected along margins of the removed tissue.
NYU Langone Medical Centre breast surgery director Freya Schnabel said: "The greatest benefit of MarginProbe is that we can perform this additional tissue removal during a patient’s initial surgery, thereby sparing them the anxiety and frustration of additional follow-up surgery.
"We found that adjunctive use of the MarginProbe device in the operating room significantly improved surgeons’ ability to identify additional cancer cells on the margins of removed tumors."